Discontinuing Melatonin with Ramelteon Therapy

Mechanism of Action and Treatment Approach

• Ramelteon is a highly selective agonist for melatonin MT1 and MT2 receptors, the exact same receptors that endogenous melatonin and supplemental melatonin activate, making combination therapy theoretically redundant rather than synergistic 1
• The American Academy of Sleep Medicine suggests ramelteon 8 mg for sleep onset insomnia, with evidence showing reductions in sleep latency of approximately 7-13 minutes 1
• The American Academy of Sleep Medicine explicitly recommends against using melatonin as first-line treatment for chronic insomnia, with weak evidence showing benefits approximately equal to harms 2, 3
• If ramelteon alone proves ineffective, switching to alternative agents with stronger evidence is recommended rather than adding melatonin 1
• Melatonin manufacturing in the United States is not FDA-regulated, raising concerns about quality and consistency that have prevented many hospitals from formulary addition 1